Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00256100
Status:
TERMINATED
Last Update Posted:
2017-04-12
First Post:
2005-11-17
Brief Title:
Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure
Sponsor:
Melbourne Health
Organization:
Melbourne Health
Study Overview
Official Title:
Assessment of the Safety and Efficacy of Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Renal Failure
Status:
TERMINATED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Teh Priincipal investigator responsible for the trial no longer employed at the study site
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this project is to assess the safety and effectiveness of fondaparinux a new drug to prevent blood clotting in the continuous dialysis machine used in intensive care patients who have kidney failure
Detailed Description:
The study hypothesis is that when used as an anticoagulant in haemofiltration fondaparinux prolongs the filter life when compared to enoxaparin
Fondaparinux is the first compound of a new class of synthetic oligosaccharides with antithrombotic effects It represents the active portion of the natural heparin molecule
The null hypothesis is that there is no difference in filter life when using fondaparinux or enoxaparin as anticoagulation for haemofiltration
Fondaparinux is the first compound of a new class of synthetic oligosaccharides with antithrombotic effects It represents the active portion of the natural heparin molecule
The null hypothesis is that there is no difference in filter life when using fondaparinux or enoxaparin as anticoagulation for haemofiltration
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None